Levodopa therapy for Parkinsonism in the Shy-Drager syndrome

Levodopa therapy for Parkinsonism in the Shy-Drager syndrome.

The results of levodopa treatment in five patients with Parkinsonism of the Shy-Drager syndrome are reported. There was no improvement in the neurological signs or functional disability in any patient. Mean values for lying and standing blood pressure increased significantly in three of the five patients during treatment, and were unchanged in the other two patients. The significance of these r...

[Shy-Drager syndrome].

Effect of xamoterol in Shy-Drager syndrome.

BACKGROUND Xamoterol, a cardioselective beta 1-adrenoceptor partial agonist, has been reported to be effective on postural hypotension. We investigated the effect of xamoterol in five patients with Shy-Drager syndrome (SDS) in relation to their prevailing sympathetic nerve activity and sensitivity of beta-adrenoceptors and the change in circadian variation of blood pressure. METHODS AND RESUL...

A case of Shy, Drager Syndrome

SUMMARY Shy, Drager syndrome is multi system degeneration of the central nervous system along with pandysautonomia. It begins after age 50 and affects men twice as women. The cardinal manifestation are due to basal ganglia and orthostatic hypotension. In spite of extrapyramidal involvement the response is poor to conventional anti-Parkinsonian medications and if this is the case in a middle ag...

Shy-Drager syndrome: recognition and management.

Shy-Drager syndrome is an uncommon disorder in which the patient experiences progressive autonomic failure. It is a multisystem degenerative disease that involves the central autonomic, cerebellar, basal ganglia, pyramidal, or spinal motor neurons. The mean age of onset is 55 years. A male predominance is noted, with a 2 or 3:1 ratio. About 11 percent of patients with orthostatic hypotension ha...